<h2 data-section-id="1vyfeio" data-start="0" data-end="23"><strong>Endometriosis Market</strong></h2>
<p data-start="25" data-end="710">The <a href="https://www.delveinsight.com/report-store/endometriosis-market"><strong>endometriosis market</strong></a> across the 7MM was valued at nearly USD 1.5 billion in 2025 and is projected to expand at a CAGR of 6.2% during 2026-2036. Increasing disease awareness, earlier diagnosis, and advances in noninvasive diagnostic technologies are supporting market growth. The US accounted for nearly 87% of the total market share in 2025, reflecting high diagnosis and treatment adoption. Emerging therapies targeting chronic pain, inflammation, and lesion persistence are expected to reshape the treatment landscape. Additionally, biomarker-based diagnostics and fertility-friendly therapies may improve patient outcomes and broaden treatment accessibility in the coming years.</p>
<h3 data-start="712" data-end="734"><strong data-start="712" data-end="734">Key Market Drivers</strong></h3>
<ul data-start="735" data-end="916">
<li data-section-id="udthdl" data-start="735" data-end="773">Rising prevalence of endometriosis</li>
<li data-section-id="bvefuu" data-start="774" data-end="830">Increasing awareness and early diagnosis initiatives</li>
<li data-section-id="eajm0j" data-start="831" data-end="874">Advancements in diagnostic technologies</li>
<li data-section-id="6yi0tp" data-start="875" data-end="916">Strong pipeline of emerging therapies</li>
</ul>
<h2 data-section-id="1vmam9b" data-start="923" data-end="952"><strong>Endometriosis Epidemiology</strong></h2>
<p data-start="954" data-end="1689">Endometriosis is a chronic gynecological disorder characterized by endometrial-like tissue growing outside the uterus, commonly affecting the ovaries, fallopian tubes, and pelvic cavity. In 2025, the diagnosed prevalent cases across the 7MM reached nearly 6 million. In the US alone, gynecologists managed approximately 3 million diagnosed cases. Epidemiological trends indicate a higher burden among women aged 30-49 years in Japan. In EU4 and the UK, Stage I disease represented the largest proportion of diagnosed cases. Delayed diagnosis remains a major challenge due to overlapping symptoms, including <a href="https://www.delveinsight.com/report-store/dysmenorrhea-market"><strong>dysmenorrhea</strong></a>, <a href="https://www.delveinsight.com/report-store/female-infertility-market"><strong>infertility</strong></a>, excessive bleeding, and pelvic pain, often leading to prolonged disease progression before treatment.</p>
<h3 data-start="1691" data-end="1718"><strong data-start="1691" data-end="1718">Epidemiology Highlights</strong></h3>
<ul data-start="1719" data-end="2067">
<li data-section-id="183h63m" data-start="1719" data-end="1779">Total diagnosed prevalent cases in 7MM: 6 million (2025)</li>
<li data-section-id="16mo6zb" data-start="1780" data-end="1824">US gynecologist-managed cases: 3 million</li>
<li data-section-id="yck414" data-start="1825" data-end="1950">Japan age-specific prevalence:
<ul data-start="1862" data-end="1950">
<li data-section-id="6reher" data-start="1862" data-end="1881">15-19 years: 7%</li>
<li data-section-id="1ywf3ud" data-start="1884" data-end="1904">20-29 years: 26%</li>
<li data-section-id="nr4cmp" data-start="1907" data-end="1927">30-39 years: 33%</li>
<li data-section-id="1qnkcdy" data-start="1930" data-end="1950">40-49 years: 34%</li>
</ul>
</li>
<li data-section-id="105loon" data-start="1951" data-end="2067">EU4 and UK stage-specific cases:
<ul data-start="1990" data-end="2067">
<li data-section-id="1yyid33" data-start="1990" data-end="2006">Stage I: 50%</li>
<li data-section-id="15oga5x" data-start="2009" data-end="2026">Stage II: 24%</li>
<li data-section-id="xbmv4v" data-start="2029" data-end="2047">Stage III: 14%</li>
<li data-section-id="1jfnsr3" data-start="2050" data-end="2067">Stage IV: 12%</li>
</ul>
</li>
</ul>
<h2 data-section-id="95vmti" data-start="2074" data-end="2099"><strong>Endometriosis Pipeline</strong></h2>
<p data-start="2101" data-end="2849">The <a href="https://www.delveinsight.com/report-store/endometriosis-pipeline-insight"><strong>endometriosis pipeline</strong></a> is evolving with the development of nonhormonal, fertility-sparing, and disease-modifying therapies designed to address persistent pain and lesion progression. Current approved therapies include <span class="whitespace-normal">AbbVie</span>&rsquo;s <a href="https://www.delveinsight.com/report-store/orilissa-elagolix-drug-insight-and-market"><strong>ORILISSA</strong></a>, MYFEMBREE/RYEQO from <span class="whitespace-normal">Pfizer</span> and Myovant, and YSELTY from <span class="whitespace-normal">Kissei Pharmaceutical</span>. Emerging candidates such as HMI-115, Merigolix/TU2670, Vipoglanstat (GS-248), and VML-0501 are targeting novel mechanisms including prolactin receptor antagonism and GnRH inhibition. Among emerging therapies, HMI-115 is anticipated to generate the highest revenue by 2036 in the 7MM, highlighting growing interest in innovative treatment approaches.</p>
<h3 data-start="2851" data-end="2869"><strong data-start="2851" data-end="2869">Emerging Drugs</strong></h3>
<ul data-start="2870" data-end="3007">
<li data-section-id="s9uj97" data-start="2870" data-end="2903">HMI-115 - Bayer/Hope Medicine</li>
<li data-section-id="37celm" data-start="2904" data-end="2948">Merigolix/TU2670 - Tiumbio/Hansoh Pharma</li>
<li data-section-id="1b9dwju" data-start="2949" data-end="2984">Vipoglanstat (GS-248) - TiumBio</li>
<li data-section-id="q8n949" data-start="2985" data-end="3007">VML-0501 - Viramal</li>
</ul>
<h3 data-start="3009" data-end="3028"><strong data-start="3009" data-end="3028">Key Unmet Needs</strong></h3>
<ul data-start="3029" data-end="3248" data-is-last-node="" data-is-only-node="">
<li data-section-id="1mx772o" data-start="3029" data-end="3068">Lack of disease-modifying therapies</li>
<li data-section-id="ti1idh" data-start="3069" data-end="3122">Limited nonhormonal and fertility-sparing options</li>
<li data-section-id="ywjevn" data-start="3123" data-end="3156">High recurrence after surgery</li>
<li data-section-id="19z5cxl" data-start="3157" data-end="3204">Inadequate long-term chronic-use treatments</li>
<li data-section-id="1a5s8ao" data-start="3205" data-end="3248" data-is-last-node="">Persistent pain despite lesion management</li>
</ul>

Endometriosis Market

Endometriosis Market Infographics

Endometriosis Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape